VIGL Vigil Neuroscience
- 2.580
- -0.190-6.86%
- 2.590
- +0.010+0.39%
Vigil Neuroscience News
Vigil Neuroscience Analyst Ratings
Vigil Neuroscience Analyst Ratings
Buy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readouts
Vigil Neuroscience Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)
Buy Rating Affirmed: Vigil Neuroscience's Advancing TREM2 Programs and Strong Financial Position
Wedbush Trims Vigil Neuroscience Price Target to $22 From $23, Maintains Outperform Rating
Stifel Nicolaus Sticks to Its Buy Rating for Vigil Neuroscience Inc (VIGL)
Analysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)
Morgan Stanley Downgrades Vigil Neuroscience to Underweight, Lowers Price Target to $4
Vigil Neuroscience Analyst Ratings
Promising Clinical Trial Results and Safety Profile Bolster Buy Rating for Vigil Neuroscience Inc: An In-depth Analysis
Wedbush Reiterates Outperform on Vigil Neuroscience, Maintains $23 Price Target
Vigil Neuroscience Analyst Ratings
Analysts Conflicted on These Healthcare Names: Vigil Neuroscience Inc (VIGL), Medicine Man Technologies (OtherSHWZ) and BioLife Solutions (BLFS)
Promising IGNITE Trial Results Bolster Buy Rating for Vigil Neuroscience Inc: An Analysis of VGL101's Potential in ALSP Treatment
Vigil Neuroscience's Robust Growth Potential: A Buy Recommendation Based on Innovative Pipeline and Anticipated Phase 2 IGNITE Study Results
Wedbush Reiterates Outperform on Vigil Neuroscience, Maintains $23 Price Target
Vigil Neuroscience Analyst Ratings
Vigil Neuroscience Inc: Potential for Accelerated Approval and Proof of Concept for VGL-101 Bolsters Buy Rating
Analysis
Price Target
No Data
